CG Oncology plans IPO plunge

Today’s Big News

Jan 3, 2024

Boehringer bets $2B in biobucks to unlock siRNA targets for MASH treatments


Get ready for the Roche (Remix), ft. a $30M small molecule deal


CG Oncology plans IPO plunge ahead of phase 3 bladder cancer drug readout


Sciwind blows into GLP-1 contention with pivotal data on Chinese rival to Novo, Lilly


‘An attractive opportunity for investing’: Goldman Sachs closes $650M fund aimed at biotechs


Anavex stock sinks 30% as lead asset fails to improve Rett syndrome in children


Roche designs new antibiotic to fight deadly A. baumannii infections

The Top Line Podcast: Don’t miss out on the newest episode. Listen now.

 

Featured

Boehringer bets $2B in biobucks to unlock siRNA targets for MASH treatments

Boehringer Ingelheim is having another crack at using RNA to treat metabolic-associated steatohepatitis (MASH). Six years after inking deals for a pair of prospects, the German drugmaker has committed more than $2 billion in biobucks to enter into a multi-target pact with a Chinese biotech and its Swedish subsidiary.
 

Top Stories

Get ready for the Roche (Remix), ft. a $30M small molecule deal

Roche is ready for the remix—Therapeutics that is. The Swiss pharma has signed a $30 million upfront deal that could rise to $1 billion down the line to develop new small molecules.

CG Oncology plans IPO plunge ahead of phase 3 bladder cancer drug readout

Five months after reeling in $105 million from a pre-IPO crossover round, CG Oncology is now ready to take the plunge and go public.

Sciwind blows into GLP-1 contention with pivotal data on Chinese rival to Novo, Lilly

Sciwind Biosciences has furthered its plans to challenge Novo Nordisk’s Ozempic for the Chinese type 2 diabetes market, linking its rival GLP-1 drug to reductions in blood glucose and body weight in a phase 3 clinical trial.

‘An attractive opportunity for investing’: Goldman Sachs closes $650M fund aimed at biotechs

Goldman Sachs is planning to make a splash in the life sciences sector, closing a $650 million for its first fund aimed at the drug development space.

Anavex stock sinks 30% as lead asset fails to improve Rett syndrome in children

Anavex Life Sciences’ lead asset has failed to significantly improve disease characteristics in a pediatric Rett syndrome trial, with the company pointing the blame toward a high placebo effect.

Roche designs new antibiotic to fight deadly A. baumannii infections

Researchers at Roche have developed a novel antibiotic with the ability to fight a dangerous drug-resistant bacteria that kills in up to 60% of infections.

WuXi CRDMO spinoff WuXi XDC inks partnership with IntoCell

WuXi XDC, which spun off from WuXi Bio And WuXi STA in a November IPO, is partnering up with the South Korean biotech IntoCell.

GlucoTrack’s 2-year implantable CGM boasts high accuracy in early tests, paving the way for human trials

A new set of early study results have suggested that in addition to offering a longer-term alternative to standard CGMs, GlucoTrack’s technology also shows promise in improving on its competitors’ accuracy.

Inside AbbVie's $10B buyout of ImmunoGen—and the bidding war it swooped in on

According to a recent securities filing, AbbVie only entered the ImmunoGen bidding war after other buyout interest led the ADC specialist to widen its pool of potential purchasers. When it came down to the final three players, AbbVie's offer blew the others out of the water.

Medicare is overpaying for certain common, over-the-counter drugs: study

Medicare Part D will cover certain over-the-counter products when prescribed by a clinician, and when it does, the program pays far more for these drugs, according to a recent study.
 
Fierce podcasts

Don’t miss an episode

'The Top Line': The year in biotech

This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her.
 

Resources

Whitepaper

Developing and Manufacturing Drugs with HPAPIs

Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient.
eBook

7 “Make or Break” Factors for Emerging Biopharma Companies

This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products.  It’s an essential resource for emerging companies with products in all stages of development.
 

Whitepaper

Quantify microbial biomarkers with high sensitivity and dynamic range

qPCR Assay Design - Quantify microbial biomarkers with high sensitivity and dynamic range
Whitepaper

Pathway to GMP Expectations for Gene-Modified Cell Therapies

Streamline your clinical cell therapy with our GMP-compliant ribonucleoprotein (RNP) manufacturing as you scale up without compromising on quality to tackle complex regulatory requirements.
Whitepaper

Fed-Batch Intensification To Increase Titer In Biologics Manufacturing

Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms.

Whitepaper

Effective Technology Transfers for Mammalian-Derived Biologics

As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. 

 

Industry Events

 

Upcoming Fierce Events

9-10
Jan
San Francisco, CA
16-18
Jan
Virtual Event
11-12
Mar
San Francisco, CA
18-20
Mar
Savannah, GA
6-8
May
Jersey City, NJ

View all events